Sept 21 (Reuters) – Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
PRAGUE, Sept 21 (Reuters) - The Czech government will restart the regulation of fuel prices…
By Susan Heavey WASHINGTON, Sept 21 (Reuters) - MS NOW, CNN and Politico said on…
By Padraic Halpin DUBLIN, Sept 21 (Reuters) - The lead EU data privacy regulator for…
Sept 21 (Reuters) - Recursion Pharmaceuticals, Inc. : * RECURSION PHARMACEUTICALS - ENTERS AMENDMENT TO…
VIDEO SHOWS: FILE FOOTAGE OF SWITZERLAND MIDFIELDER GRANIT XHAKA SHOWS: VANCOUVER, CANADA (JULY 5, 2026)…
MOSCOW, Sept 21 (Reuters) - Russian finance minister said on Monday that Moscow is planning…